79 related articles for article (PubMed ID: 321117)
21. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
22. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin.
Dubois JB; Serrou B
Cancer Res; 1976 May; 36(5):1731-4. PubMed ID: 773530
[TBL] [Abstract][Full Text] [Related]
23. Studies on the immunogical effects of BCG and its components: theoritical and therapeutic implications.
Mitchell MS
Biomedicine; 1976; 24(4):209-13. PubMed ID: 791387
[TBL] [Abstract][Full Text] [Related]
24. Combination chemotherapy-radiotherapy with and without the methanol-extraction residue of Bacillus Calmette-Guerin (MER) in small cell carcinoma of the lung: a prospective randomized trial of the Piedmont Oncology Association.
Jackson DV; Paschal BR; Ferree C; Richards F; Muss HB; Cooper MR; White DR; Stuart JJ; Spurr CL; Wells B; Sartiano G; McFarland J; McCulloch J
Cancer; 1982 Jul; 50(1):48-52. PubMed ID: 6282434
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy vs. chemoimmunotherapy with methanol extraction residue of Bacillus Calmette-Guerin (MER) in advanced breast cancer: a randomized trial by the Piedmont Oncology Association.
Muss HB; Richards F; Cooper MR; White DR; Jackson DV; Stuart JJ; Howard V; Shore A; Rhyne AL; Spurr CL
Cancer; 1981 May; 47(9):2295-301. PubMed ID: 7226124
[TBL] [Abstract][Full Text] [Related]
26. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
27. Nonspecific antigen reactions.
Klein E; Rosner D; Holtermann OA; Stoll HL; Song SY
Natl Cancer Inst Monogr; 1976 Nov; 44():87-97. PubMed ID: 799764
[TBL] [Abstract][Full Text] [Related]
28. Induction of cutaneous plasma cell tumor as a complication of adjuvant immunotherapy with methanol extraction residue of bacillus Calmette-Guérin.
Suster SM; Ronnen M; Huszar M; Pines A; Schibi-Brilliant G
Oncology; 1987; 44(5):279-82. PubMed ID: 3670794
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
30. Vaccination of neonatal calves with Mycobacterium bovis BCG induces protection against intranasal challenge with virulent M. bovis.
Hope JC; Thom ML; Villarreal-Ramos B; Vordermeier HM; Hewinson RG; Howard CJ
Clin Exp Immunol; 2005 Jan; 139(1):48-56. PubMed ID: 15606613
[TBL] [Abstract][Full Text] [Related]
31. Bacillus Calmette-Guerin in the treatment of neoplastic disease.
Laucius JF; Bodurtha AJ; Mastrangelo MJ; Creech RH
J Reticuloendothel Soc; 1974 Dec; 16(6):347-73. PubMed ID: 4616079
[No Abstract] [Full Text] [Related]
32. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
33. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
Mack D; Höltl W; Bassi P; Brausi M; Ferrari P; de Balincourt C; Sylvester R;
J Urol; 2001 Feb; 165(2):401-3. PubMed ID: 11176382
[TBL] [Abstract][Full Text] [Related]
34. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
35. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
Bjornsson S; Takita H; Kuberka N; Preisler H; Catane H; Higby D; Henderson E
Cancer Treat Rep; 1978 Apr; 62(4):505-10. PubMed ID: 350388
[TBL] [Abstract][Full Text] [Related]
36. NTP Toxicology and Carcinogenesis Studies of 3,3'-Dimethylbenzidine Dihydrochloride (CAS No. 612-82-8) in F344/N Rats (Drinking Water Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1991 Jun; 390():1-238. PubMed ID: 12637969
[TBL] [Abstract][Full Text] [Related]
37. Systemic epithelioid granulomata following immunotherapy with methanol extracted residue of bacillus Calmette-Guérin.
Jaffrey IS
Cancer Treat Rep; 1978 Apr; 62(4):573. PubMed ID: 657153
[No Abstract] [Full Text] [Related]
38. Influence of oil concentration on the efficacy of tumor regression by emulsified components of mycobacteria.
Yarkoni E; Rapp HJ
Cancer Res; 1979 Feb; 39(2 Pt 1):535-7. PubMed ID: 761228
[TBL] [Abstract][Full Text] [Related]
39. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
[TBL] [Abstract][Full Text] [Related]
40. Phase I toxicity study of methanol-extracted residue of Bacillus Calmette-Guérin by the iv route.
Maroun JA; Quesada JR; Hersh EM; Gutterman JU; Richman S; Schwarz MA; Parker N
Cancer Treat Rep; 1979; 63(11-12):1781-6. PubMed ID: 393379
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
